BioMarin has provided the following update on redosing of drisapersen for a new clinical trial. Ambulation will not be an inclusion or exclusion criterion for enrollment, but boys will need to have been previously dosed as part of a clinical trial.
BioMarin Update on Duchenne Muscular Dystrophy…
Added by Ryan Fischer on April 14, 2015 at 9:00am — No Comments
Earlier this month Sarepta announced a change in leadership, with CMO Ed Kaye taking over as interim CEO.
Following that announcement the team at Sarepta organized a call with Duchenne patient organizations and foundations to update them…
Added by Ryan Fischer on April 13, 2015 at 11:00am — No Comments